BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · IEX Real-Time Price · USD
3.320
+0.220 (7.10%)
At close: Feb 27, 2024, 4:00 PM
3.370
+0.050 (1.51%)
After-hours: Feb 27, 2024, 7:59 PM EST
7.10%
Market Cap 94.18M
Revenue (ttm) 1.24M
Net Income (ttm) -211.61M
Shares Out 30.38M
EPS (ttm) -7.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,516,711
Open 3.130
Previous Close 3.100
Day's Range 3.100 - 3.500
52-Week Range 1.910 - 32.870
Beta 0.49
Analysts Buy
Price Target 10.83 (+226.21%)
Earnings Date Mar 7, 2024

About BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation as... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 183
Stock Exchange NASDAQ
Ticker Symbol BTAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $10.83, which is an increase of 226.21% from the latest price.

Price Target
$10.83
(226.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioXcel Therapeutics Announces Termination of Proposed Public Offering

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...

14 days ago - GlobeNewsWire

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability

15 days ago - GlobeNewsWire

BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

19 days ago - GlobeNewsWire

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center

21 days ago - GlobeNewsWire

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

Aligns with Company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer's patients

22 days ago - GlobeNewsWire

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer's disease and BXCL502 as a potential treatment for chronic us...

2 months ago - GlobeNewsWire

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D.

2 months ago - GlobeNewsWire

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer's disease and BXCL502 as a potential treatment Dr. Sandra Com...

3 months ago - GlobeNewsWire

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable Alz...

3 months ago - GlobeNewsWire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab),  compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 tria...

3 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024 Fentanyl adulterated or associated with xylazine (FAAX) designated an emerging threat...

4 months ago - GlobeNewsWire

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...

4 months ago - GlobeNewsWire

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Na...

4 months ago - GlobeNewsWire

BioXcel Therapeutics shares pop after audit of Alzheimer's trial data

Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of Alzheimer's trial data found no issues impacting the data's ...

4 months ago - Market Watch

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

No evidence of misconduct or fraud found beyond instance previously reported 1 No findings identified that impact data integrity Company believes audit findings support reliability of positive TRANQUI...

4 months ago - GlobeNewsWire

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on...

4 months ago - Business Wire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Median overall survival of 13.6 months with BXCL701 + KEYTRUDA ® ( pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phas...

5 months ago - GlobeNewsWire

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI ™ market exclusivity through receipt of two Notices of Allowance NEW HAVEN, Con...

5 months ago - GlobeNewsWire

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("...

6 months ago - Accesswire

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LAS ANGELES, CA / ACCESSWIRE / September 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("...

6 months ago - Accesswire

BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, ...

6 months ago - Business Wire

Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit

RADNOR, Pa. , Sept. 3, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United Stat...

6 months ago - PRNewsWire

BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

NEW YORK , Sept. 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021...

6 months ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves...

6 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Aug. 31, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS ...

6 months ago - PRNewsWire